Zobrazeno 1 - 10
of 10
pro vyhledávání: '"S L, Crampton"'
Autor:
Philip A. Allen, S. L. Crampton
Publikováno v:
AAPG Bulletin. 79
The peripheral upwarp (forebulge) associated with early foreland basin evolution may be recorded as an unconformity at the base of the foreland basin fill. A forebulge unconformity represents a distinctive type of megasequence boundary. Forward model
Publikováno v:
Cancer research. 37(6)
Chartreusin has exhibited significant therapeutic activity against three experimental mouse tumors (ascitic P388, L1210 leukemia, and B16 melanoma) when tumor cells were inoculated i.p. and drug was administered i.p. In further testing against P388 l
Publikováno v:
Investigational new drugs. 3(3)
Menogarol is a new anthracycline undergoing phase I clinical trial. We report here the lethality after 2 hr exposure to 2 drug combinations of menogarol and several antitumor agents. A new statistical procedure was used to identify synergistic combin
Publikováno v:
Cancer research. 42(9)
CC-1065 (NSC 298223) is the most cytotoxic agent tested against cells in culture in our laboratory. The 50% lethal doses for exponentially growing B16 melanoma and Chinese hamster ovary cells were 0.44 and 0.14 ng/ml, respectively, as compared to 35
Publikováno v:
Cancer research. 41(1)
Nogalamycin is an anthracycline antibiotic which was markedly cytotoxic in vitro and was active against several tumor systems in vivo. We compare here the lethality of several nogalamycin analogs against Chinese hamster ovary (CHO), mouse leukemia (L
Publikováno v:
Cancer research. 39(12)
Publikováno v:
Cancer research. 41(12 Pt 1)
The effect of 7-con-O-methylnogarol (7-OMEN) on the survival of exponentially growing and plateau-phase Chinese hamster ovary cells was determined in a cloning assay. After 2 hr of exposure, the 50% lethal dose for exponential and plateau-phase cells
Publikováno v:
Cancer research. 41(3)
Publikováno v:
Cancer research. 44(5)
Didemnins are a new class of cyclic depsipeptides in which didemnin A is the major component, didemnin B the minor component, and a trace of didemnin C is present. Didemnin B was more potent than was didemnin A against B16 melanoma and P388 leukemia
Publikováno v:
Cancer research. 43(9)
CC-1065 is the most potent antitumor agent tested in our laboratory. It is lethal to B16 and CHO cells and to a variety of human tumors in the clonogenic assay at 1 ng/ml and is effective against L1210 leukemia and B16 melanoma in vivo at 1 to 50 mic